Intellinetics, Inc. (NYSE American: INLX), a digital transformation solutions provider, announced financial results for the third quarter of 2025 and nine months ended September 30, 2025.

Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private ...